<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">AIDS</journal-id>
      <journal-id journal-id-type="iso-abbrev">AIDS</journal-id>
      <journal-id journal-id-type="publisher-id">AIDS</journal-id>
      <journal-title-group>
        <journal-title>AIDS (London, England)</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0269-9370</issn>
      <issn pub-type="epub">1473-5571</issn>
      <publisher>
        <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26959357</article-id>
      <article-id pub-id-type="pmc">4788062</article-id>
      <article-id pub-id-type="doi">10.1097/QAD.0000000000001022</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Correspondence</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Subdominant Gag-specific anti-HIV efficacy in an HLA-B<sup>&#x2217;</sup>57-positive elite controller</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Leitman</surname>
            <given-names>Ellen M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Willberg</surname>
            <given-names>Christian B.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>b</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Burgh-Thomas</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>c</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Streeck</surname>
            <given-names>Hendrik</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>d</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Goulder</surname>
            <given-names>Philip J.R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>a</sup>
</xref>
          <xref ref-type="aff" rid="aff5">
<sup>e</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Matthews</surname>
            <given-names>Philippa C.</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>f</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>a</label>Department of Paediatrics</aff>
      <aff id="aff2"><label>b</label>Nuffield Department of Medicine, University of Oxford, Oxford</aff>
      <aff id="aff3"><label>c</label>Gloucestershire Royal Hospital, Gloucester, UK</aff>
      <aff id="aff4"><label>d</label>Institute for HIV Research, University Hospital Essen, University Duisburg-Essen, Essen, Germany</aff>
      <aff id="aff5"><label>e</label>HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa</aff>
      <aff id="aff6"><label>f</label>Department of Infectious Diseases and Microbiology, Oxford University Hospitals NGS Trust, John Radcliffe Hospital, Oxford, UK.</aff>
      <author-notes>
        <corresp>Correspondence to Ellen M. Leitman, The Peter Medawar Building for Pathogen Research, South Parks Road, Oxford, OX1 3SY, UK. Tel: +44 1865 281880; e-mail: <email>ellen.leitman@st-hughs.ox.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>27</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>07</day>
        <month>3</month>
        <year>2016</year>
      </pub-date>
      <volume>30</volume>
      <issue>6</issue>
      <fpage>972</fpage>
      <lpage>974</lpage>
      <history>
        <date date-type="received">
          <day>09</day>
          <month>12</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>16</day>
          <month>12</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2016 Wolters Kluwer Health, Inc. All rights reserved.</copyright-statement>
        <copyright-year>2016</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0">
          <license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>
</license-p>
        </license>
      </permissions>
      <self-uri xlink:type="simple" xlink:href="aids-30-972.pdf"/>
      <custom-meta-group>
        <custom-meta>
          <meta-name>OPEN-ACCESS</meta-name>
          <meta-value>TRUE</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <p>Despite the discovery of HIV over three decades ago, the 2008 &#x2018;Berlin patient&#x2019; is the only case of sustained HIV remission. Other cases of apparent &#x2018;cure&#x2019; eventually relapsed [<xref rid="R1" ref-type="bibr">1</xref>] and although early antiretroviral therapy (ART) has recently gained traction as a factor contributing to remission [<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>], most cases are likely to relapse [<xref rid="R4" ref-type="bibr">4</xref>]. In contrast, relapse in &#x2018;elite controllers&#x2019; of HIV infection is less common. These are ART-na&#xEF;ve individuals who spontaneously suppress viremia to undetectable levels. Approximately 40% of elite controllers express HLA-B<sup>&#x2217;</sup>57 [<xref rid="R5" ref-type="bibr">5</xref>], an example being the original 1999 &#x2018;Berlin patient&#x2019;, in whom virologic control has been maintained for &gt;15 years to date [<xref rid="R6" ref-type="bibr">6</xref>].</p>
    <p>Mechanisms proposed to explain HLA-B<sup>&#x2217;</sup>57-mediated immune control include immunodominant CD8<sup>+</sup> T-cell-targeting of multiple conserved Gag epitopes from which mutational escape is detrimental to viral fitness, characteristics of the T-cell receptor on HLA-B<sup>&#x2217;</sup>57-restricted CD8<sup>+</sup> T cells, HLA-B<sup>&#x2217;</sup>57-peptide binding affinity, and HLA-B<sup>&#x2217;</sup>57 cross-talk with innate immune cells [<xref rid="R7" ref-type="bibr">7</xref>]. However, some HLA-B<sup>&#x2217;</sup>57-positive elite controllers have no detectable Gag-specific responses without ex-vivo expansion [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]. Here, we studied one such elite controller, to determine whether the immunodominant CD8<sup>+</sup> T-cell response in such cases mediates the most potent antiviral efficacy, as Gag-specific CD8<sup>+</sup> T-cell responses typically have greater capacity to inhibit viral replication than non-Gag specificities [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R11" ref-type="bibr">11</xref>].</p>
    <p>An African-Caribbean female was recruited in the UK at 52 years of age in 2013. She had been diagnosed with HIV in 1991, an estimated 2 years after heterosexual transmission in Jamaica (and hence is referred to here as the &#x2018;1991 Jamaica patient&#x2019;). Our study was approved by the Oxford Research Ethics Committee and the patient provided written informed consent.</p>
    <p>For more than 24 years, she has remained ART-na&#xEF;ve and aviremic with a healthy CD4<sup>+</sup> T-cell count (median 1237&#x200A;cells/&#x3BC;l) (Fig. <xref ref-type="fig" rid="F1">1</xref>a). Despite being HLA-B<sup>&#x2217;</sup>57&#x200A;:&#x200A;03-positive, she demonstrated only two HIV-specific CD8<sup>+</sup> T-cell responses detectable by ELISPOT assay, neither greater than 60 spot forming units (SFC)/million peripheral blood mononuclear cell (PBMC) and none detectable by tetramer staining (Fig. <xref ref-type="fig" rid="F1">1</xref>b and c). This is in contrast to the &#x2018;1999 Berlin patient&#x2019;, who had a dominant HLA-B<sup>&#x2217;</sup>57-restricted Nef-HW9 response of 3000&#x200A;SFC/million PBMC [<xref rid="R6" ref-type="bibr">6</xref>] (Fig. <xref ref-type="fig" rid="F1">1</xref>b). One of the two significant ELISPOT responses in the 1991 Jamaica patient was also against this same Nef-HW9 epitope (Fig. <xref ref-type="fig" rid="F1">1</xref>b). However, via peptide stimulation of memory T-cell responses [<xref rid="R8" ref-type="bibr">8</xref>], we identified five HLA-B<sup>&#x2217;</sup>57-restricted responses (Fig. <xref ref-type="fig" rid="F1">1</xref>c), three of which we tested for their ability to inhibit HIV replication. Bulk CD8<sup>+</sup> T cells demonstrated weak ex-vivo ability to suppress viral replication (Fig. <xref ref-type="fig" rid="F1">1</xref>d and e), fitting the profile of a subset of HLA-B<sup>&#x2217;</sup>57-positive elite controllers [<xref rid="R12" ref-type="bibr">12</xref>]. Of the three expanded HLA-B<sup>&#x2217;</sup>57-restricted CD8<sup>+</sup> T-cell specificities tested, Gag-TW10-specific CD8<sup>+</sup> T cells were significantly the most potent in suppressing HIV replication, followed by Nef-KF9 and then Nef-HW9 (Fig. <xref ref-type="fig" rid="F1">1</xref>d and e).</p>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p>Clinical profile and anti-HIV suppressive activity of the 1991 Jamaica patient.</p>
      </caption>
      <graphic xlink:href="aids-30-972-g001"/>
      <p>(a) CD4<sup>+</sup> T-cell count and HIV RNA viral load measurements. &#x2018;0&#x2019; is time of diagnosis. Limit of detection (LOD) for viral load is 40&#x200A;copies/ml (gray area) and measurements are shown at 40&#x200A;copies/ml for convenience. Although sequencing was unsuccessful due to lack of circulating virus, the 1991 Jamaica patient was likely infected with subtype-B HIV predominant in Jamaica. (b) ELISPOT CD8<sup>+</sup> T-cell responses in unstimulated peripheral blood mononuclear cells (PBMCs) in the 1991 Jamaica patient (22 years postdiagnosis) to subtype-B consensus HLA-B<sup>&#x2217;</sup>57-restricted defined optimal epitopes. Responses were considered positive if they were at least three times the mean number of spot forming colonies (SFC) in the four negative control wells and had to be greater than 50&#x200A;SFC/10<sup>6</sup> PBMC (dotted line). CD8<sup>+</sup> T-cell responses for the 1999 Berlin patient are shown to highlight the different patterns of responses (not for direct comparisons as the assays were done in different laboratories at different times). Nt&#x200A;=&#x200A;not tested. (c) PBMC (23 years postdiagnosis) were stimulated with a panel of 30&#x200A;HLA-B<sup>&#x2217;</sup>57/81&#x200A;:&#x200A;01-restricted optimal peptides. Five previously undetectable HLA-B<sup>&#x2217;</sup>57-restricted responses were discovered poststimulation, but no HLA-B<sup>&#x2217;</sup>81&#x200A;:&#x200A;01-restricted responses. Three of these five responses were successfully expanded and tested in (d). Gated on live CD3<sup>+</sup>CD4<sup>&#x2013;</sup> cells around CD8<sup>+</sup>tetramer+ population; numbers indicate % tetramer+CD8<sup>+</sup> cells (of CD3<sup>+</sup>CD4<sup>&#x2013;</sup>). (d) Viral replication in HLA-B<sup>&#x2217;</sup>57&#x200A;:&#x200A;03-expressing H9 cells infected with NL4-3-GFP and cultured alone (&#x2018;targets alone&#x2019;), with unstimulated bulk CD8<sup>+</sup> T cells (left) or stimulated epitope-specific CD8<sup>+</sup> T cells (right) of the 1991 Jamaica patient (23 years postdiagnosis). Each symbol represents the mean of three replicates, error bars represent the SEM. (e) Suppressive capacity (log<sub>10</sub> fold decrease in % of infected GFP<sup>+</sup> cells) of bulk unstimulated CD8<sup>+</sup> T cells or stimulated epitope-specific CD8<sup>+</sup> T cells of the 1991 Jamaica patient. Results were compared with &#x2018;bulk CD8&#x2019; (ANOVA with Dunnett's multiple comparison post-test). <sup>&#x2217;</sup>
<italic>P</italic>&#x200A;&lt;&#x200A;0.05, <sup>&#x2217;&#x2217;</sup>
<italic>P</italic>&#x200A;&lt;&#x200A;0.01, <sup>&#x2217;&#x2217;&#x2217;</sup>
<italic>P</italic>&#x200A;&lt;&#x200A;0.001, ns&#x200A;=&#x200A;not significant (<italic>P</italic>&#x200A;&gt;&#x200A;0.05).</p>
    </fig>
    <p>The study of this HLA-B<sup>&#x2217;</sup>57-positive individual confirms that, in spite of HIV-specific responses being low frequency or undetectable by tetramer staining or ELISPOT assay, strong responses could be &#x2018;recalled&#x2019; from memory, as previously reported [<xref rid="R8" ref-type="bibr">8</xref>]. Among these, Gag-TW10-specific CD8<sup>+</sup> T cells were more potent at inhibiting viral replication than Nef-KF9-specific cells, despite the latter being a stronger response in ELISPOT assays. These data support previous findings in subjects chronically infected with HIV [<xref rid="R13" ref-type="bibr">13</xref>] indicating that subdominant responses may be more efficacious in terms of control of viremia. The findings here are extended also to the case of an HLA-B<sup>&#x2217;</sup>57-positive elite controller. Although, like the 1999 Berlin patient, this is a single case report, the data are consistent with the hypothesis that HLA-B<sup>&#x2217;</sup>57-mediated Gag-specific targeting by CD8<sup>+</sup> T cells confers benefit to the host in HIV infection [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R14" ref-type="bibr">14</xref>] and that vaccine induction of broad Gag-specific CD8<sup>+</sup> T-cell responses would tend to increase immune control in HIV infection [<xref rid="R15" ref-type="bibr">15</xref>].</p>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors would like to thank the 1991 Jamaica patient for her participation in our study. The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CD3.4 Bi-specific Monoclonal Antibody (Cat#12278) from Drs Johnson Wong and Galit Alter.</p>
      <p>Funding: This work was supported by NIHR and OUCAGS to PCM; by the National Institutes of Health [R01AI46995 to PJRG]; and by the Clarendon Foundation to EML.</p>
      <sec>
        <title>Conflicts of interest</title>
        <p>There are no conflicts of interest.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henrich</surname><given-names>TJ</given-names></name><name><surname>Hanhauser</surname><given-names>E</given-names></name><name><surname>Marty</surname><given-names>FM</given-names></name><name><surname>Sirignano</surname><given-names>MN</given-names></name><name><surname>Keating</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>TH</given-names></name><etal/></person-group>
<article-title>
<bold>Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases</bold>
</article-title>. <source><italic>Ann Intern Med</italic></source>
<year>2014</year>; <volume>161</volume>:<fpage>319</fpage>&#x2013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">25047577</pub-id></mixed-citation>
      </ref>
      <ref id="R2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saez-Cirion</surname><given-names>A</given-names></name><name><surname>Bacchus</surname><given-names>C</given-names></name><name><surname>Hocqueloux</surname><given-names>L</given-names></name><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><name><surname>Girault</surname><given-names>I</given-names></name><name><surname>Lecuroux</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>
<bold>Posttreatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study</bold>
</article-title>. <source><italic>PLoS Pathog</italic></source>
<year>2013</year>; <volume>9</volume>:<fpage>e1003211</fpage>.<pub-id pub-id-type="pmid">23516360</pub-id></mixed-citation>
      </ref>
      <ref id="R3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frange</surname><given-names>P</given-names></name><name><surname>Faye</surname><given-names>A</given-names></name><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><name><surname>Bellaton</surname><given-names>E</given-names></name><name><surname>Deschamps</surname><given-names>D</given-names></name><name><surname>Angin</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>
<bold>HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French Pediatric Cohort ANRS EPF-CO10. A case report</bold>
</article-title>. <source><italic>Lancet HIV</italic></source>
<year>2015</year>; <comment>[In press]</comment>.</mixed-citation>
      </ref>
      <ref id="R4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Luzuriaga</surname><given-names>K</given-names></name><name><surname>Gay</surname><given-names>H</given-names></name><name><surname>Ziemniak</surname><given-names>C</given-names></name><name><surname>Sanborn</surname><given-names>KB</given-names></name><name><surname>Somasundaran</surname><given-names>M</given-names></name><name><surname>Rainwater-Lovett</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>
<bold>Viremic relapse after HIV-1 remission in a perinatally infected child</bold>
</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2015</year>; <volume>372</volume>:<fpage>786</fpage>&#x2013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">25693029</pub-id></mixed-citation>
      </ref>
      <ref id="R5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pereyra</surname><given-names>F</given-names></name><name><surname>Addo</surname><given-names>MM</given-names></name><name><surname>Kaufmann</surname><given-names>DE</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>T</given-names></name><name><surname>Rathod</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>
<bold>Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy</bold>
</article-title>. <source><italic>J Infect Dis</italic></source>
<year>2008</year>; <volume>197</volume>:<fpage>563</fpage>&#x2013;<lpage>571</lpage>.<pub-id pub-id-type="pmid">18275276</pub-id></mixed-citation>
      </ref>
      <ref id="R6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jessen</surname><given-names>H</given-names></name><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Streeck</surname><given-names>H</given-names></name></person-group>
<article-title>
<bold>How a single patient influenced HIV research: 15-year follow-up</bold>
</article-title>. <source><italic>N Engl J Med</italic></source>
<year>2014</year>; <volume>370</volume>:<fpage>682</fpage>&#x2013;<lpage>683</lpage>.<pub-id pub-id-type="pmid">24521131</pub-id></mixed-citation>
      </ref>
      <ref id="R7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goulder</surname><given-names>PJ</given-names></name><name><surname>Walker</surname><given-names>BD</given-names></name></person-group>
<article-title>
<bold>HIV and HLA class I: an evolving relationship</bold>
</article-title>. <source><italic>Immunity</italic></source>
<year>2012</year>; <volume>37</volume>:<fpage>426</fpage>&#x2013;<lpage>440</lpage>.<pub-id pub-id-type="pmid">22999948</pub-id></mixed-citation>
      </ref>
      <ref id="R8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ndhlovu</surname><given-names>ZM</given-names></name><name><surname>Proudfoot</surname><given-names>J</given-names></name><name><surname>Cesa</surname><given-names>K</given-names></name><name><surname>Alvino</surname><given-names>DM</given-names></name><name><surname>McMullen</surname><given-names>A</given-names></name><name><surname>Vine</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>
<bold>Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses</bold>
</article-title>. <source><italic>J Virol</italic></source>
<year>2012</year>; <volume>86</volume>:<fpage>6959</fpage>&#x2013;<lpage>6969</lpage>.<pub-id pub-id-type="pmid">22514340</pub-id></mixed-citation>
      </ref>
      <ref id="R9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ndhlovu</surname><given-names>ZM</given-names></name><name><surname>Stampouloglou</surname><given-names>E</given-names></name><name><surname>Cesa</surname><given-names>K</given-names></name><name><surname>Mavrothalassitis</surname><given-names>O</given-names></name><name><surname>Alvino</surname><given-names>DM</given-names></name><name><surname>Li</surname><given-names>JZ</given-names></name><etal/></person-group>
<article-title>
<bold>The breadth of expandable memory CD8+ T cells inversely correlates with residual viral loads in HIV elite controllers</bold>
</article-title>. <source><italic>J Virol</italic></source>
<year>2015</year>; <volume>89</volume>:<fpage>10735</fpage>&#x2013;<lpage>10747</lpage>.<pub-id pub-id-type="pmid">26269189</pub-id></mixed-citation>
      </ref>
      <ref id="R10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Payne</surname><given-names>RP</given-names></name><name><surname>Kloverpris</surname><given-names>H</given-names></name><name><surname>Sacha</surname><given-names>JB</given-names></name><name><surname>Brumme</surname><given-names>Z</given-names></name><name><surname>Brumme</surname><given-names>C</given-names></name><name><surname>Buus</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>
<bold>Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells</bold>
</article-title>. <source><italic>J Virol</italic></source>
<year>2010</year>; <volume>84</volume>:<fpage>10543</fpage>&#x2013;<lpage>10557</lpage>.<pub-id pub-id-type="pmid">20686036</pub-id></mixed-citation>
      </ref>
      <ref id="R11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Ndhlovu</surname><given-names>ZM</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Porter</surname><given-names>LC</given-names></name><name><surname>Fang</surname><given-names>JW</given-names></name><name><surname>Darko</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>
<bold>TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection</bold>
</article-title>. <source><italic>Nat Immunol</italic></source>
<year>2012</year>; <volume>13</volume>:<fpage>691</fpage>&#x2013;<lpage>700</lpage>.<pub-id pub-id-type="pmid">22683743</pub-id></mixed-citation>
      </ref>
      <ref id="R12">
        <label>12.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lecuroux</surname><given-names>C</given-names></name><name><surname>Saez-Cirion</surname><given-names>A</given-names></name><name><surname>Girault</surname><given-names>I</given-names></name><name><surname>Versmisse</surname><given-names>P</given-names></name><name><surname>Boufassa</surname><given-names>F</given-names></name><name><surname>Avettand-Fenoel</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>
<bold>Both HLA-B&#x2217;57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers</bold>
</article-title>. <source><italic>J Virol</italic></source>
<year>2014</year>; <volume>88</volume>:<fpage>176</fpage>&#x2013;<lpage>187</lpage>.<pub-id pub-id-type="pmid">24131719</pub-id></mixed-citation>
      </ref>
      <ref id="R13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Frahm</surname><given-names>N</given-names></name><name><surname>Kiepiela</surname><given-names>P</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Linde</surname><given-names>CH</given-names></name><name><surname>Hewitt</surname><given-names>HS</given-names></name><name><surname>Sango</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>
<bold>Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes</bold>
</article-title>. <source><italic>Nat Immunol</italic></source>
<year>2006</year>; <volume>7</volume>:<fpage>173</fpage>&#x2013;<lpage>178</lpage>.<pub-id pub-id-type="pmid">16369537</pub-id></mixed-citation>
      </ref>
      <ref id="R14">
        <label>14.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kiepiela</surname><given-names>P</given-names></name><name><surname>Ngumbela</surname><given-names>K</given-names></name><name><surname>Thobakgale</surname><given-names>C</given-names></name><name><surname>Ramduth</surname><given-names>D</given-names></name><name><surname>Honeyborne</surname><given-names>I</given-names></name><name><surname>Moodley</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>
<bold>CD8+ T-cell responses to different HIV proteins have discordant associations with viral load</bold>
</article-title>. <source><italic>Nature Med</italic></source>
<year>2007</year>; <volume>13</volume>:<fpage>46</fpage>&#x2013;<lpage>53</lpage>.<pub-id pub-id-type="pmid">17173051</pub-id></mixed-citation>
      </ref>
      <ref id="R15">
        <label>15.</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Janes</surname><given-names>H</given-names></name><name><surname>Friedrich</surname><given-names>DP</given-names></name><name><surname>Krambrink</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>RJ</given-names></name><name><surname>Kallas</surname><given-names>EG</given-names></name><name><surname>Horton</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>
<bold>Vaccine-induced Gag-specific T cells are associated with reduced viremia after HIV-1 infection</bold>
</article-title>. <source><italic>J Infect Dis</italic></source>
<year>2013</year>; <volume>208</volume>:<fpage>1231</fpage>&#x2013;<lpage>1239</lpage>.<pub-id pub-id-type="pmid">23878319</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
